Edwards Lifesciences (EW) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Edwards Lifesciences Corporation (EW) insider buying and selling: no purchases, 44 sales
147 Form 4 Table I transactions filed with the SEC by Edwards Lifesciences Corporation insiders between 2025-08-25 and 2026-10-08 (15-month history): 0 open-market purchases and 44 sales, plus 103 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $2.9M by Chopra Daveen on 2026-08-26.
Edwards Lifesciences insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Edwards Lifesciences insiders filed 43 sales worth $27.7M on the open market, and no purchases.
The biggest seller was Bobo Donald E Jr (CVP, Strategy/Corp Development): $11.2M in 8 sales, out of 9 different sellers.
The largest trade of the period was a sale of $2.9M on Aug 26, 2026, by Chopra Daveen (CVP, TMTT, Surgical & IHFM). Form 4 on sec.gov (0001225208-26-007335).
Of the 43 sales, 25 (58%, $14.5M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 18 do not.
The last three months show 10 sales, against 12 in the three before. The latest sale from Oct 8, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Edwards Lifesciences has more sales than 55 of the other 58, ranks 25 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with EW's sales, largest first. The full history is in the tool above, already searched.
See all 147 EW trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-26 | 2026-08-26 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | $2.9M | S — Open-market sale2 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-05-12 | 2026-05-12 | Zovighian Bernard J | CEO | $2.8M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: By Trust 3 Form 4 footnotesF2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F3 This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-25 | 2026-02-26 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $2.0M | S — Open-market sale2 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $83.66 to $83.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 Total reflects the correction of 13,396 shares held indirectly by the Reporting Person's trust, which were previously reported as directly held. | SEC |
| 2026-05-27 | 2026-05-27 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $2.0M | S — Open-market sale Indirect holding, through: By Trust Form 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-12-08 | 2025-12-10 | Zovighian Bernard J | CEO | $1.8M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 This transaction was executed in multiple trades at prices ranging from $84.63 to $85.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-04-02 | 2026-04-02 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $1.8M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-12 | 2026-02-13 | Zovighian Bernard J | CEO | $1.7M | S — Open-market sale2 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-05-15 | 2026-05-18 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $1.5M | S — Open-market sale Indirect holding, through: 401(k) Form 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-03-11 | 2026-03-11 | Ullem Scott B. | CVP, Chief Financial Officer | $1.1M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $83.865 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $84.865 to $85.790. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-11-10 | 2025-11-10 | Ullem Scott B. | CVP, Chief Financial Officer | $1.1M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $83.270 to $83.415. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $82.270 to $83.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-04-09 | 2026-04-09 | Ullem Scott B. | CVP, Chief Financial Officer | $1.0M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-03-02 | 2026-03-02 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $974k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $85.665 to $86.380. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-01-06 | 2026-01-06 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $971k | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $84.39 to $85.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $85.40 to $86.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-12-12 | 2025-12-12 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $954k | S — Open-market sale | SEC |
| 2025-12-10 | 2025-12-10 | Bobo Donald E Jr | CVP, Strategy/Corp Development | $951k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 This transaction was executed in multiple trades at prices ranging from $83.465 to $84.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-07-28 | 2026-07-28 | Markowitz Wayne | CVP, JAPAC | $819k | S — Open-market sale | SEC |
| 2025-12-09 | 2025-12-09 | Ullem Scott B. | CVP, Chief Financial Officer | $650k | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 This transaction was executed in multiple trades at prices ranging from $84.09 to $85.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-12-10 | 2025-12-10 | Zovighian Bernard J | CEO | $322k | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: By Trust Form 4 footnoteF1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. | SEC |
| 2026-07-27 | 2026-07-27 | Zovighian Bernard J | CEO | $245k | S — Open-market sale Indirect holding, through: By Trust | SEC |
| 2026-08-28 | 2026-08-28 | Bruls Annette | CVP, EMEACLA | $238k | S — Open-market sale | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 25, 2025 and Oct 8, 2026 there is not one open-market purchase of Edwards Lifesciences Corporation: 44 sales worth $27.9M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Edwards Lifesciences Corporation's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| S | Open-market sale | 44 | $27.9M |
| F | Tax withholding (shares surrendered for taxes) | 38 | $7.1M |
| M | Option exercise | 30 | $13.6M |
| A | Grant or award | 20 | $0 |
| G | Gift | 15 | $0 |
| Total | Everything filed in the period | 147 | $48.7M |
39 of the 147 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 17 distinct people or entities have filed Edwards Lifesciences Corporation transactions: none bought on the open market and 9 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 9 who sold on the open market (44 sales in all), the three biggest sellers account for $22.0M of the $27.9M: 79% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Bobo Donald E Jr | CVP, Strategy/Corp Development | 19 | — | $11.2M (8) | 2026-05-27 |
| Zovighian Bernard J | CEO | 28 | — | $7.0M (6) | 2026-07-27 |
| Ullem Scott B. | CVP, Chief Financial Officer | 16 | — | $3.9M (4) | 2026-05-11 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | 13 | — | $3.4M (4) | 2026-09-11 |
| Markowitz Wayne | CVP, JAPAC | 13 | — | $1.0M (5) | 2026-09-14 |
| Lippis Daniel J. | CVP, TAVR | 36 | — | $925k (13) | 2026-10-08 |
| Bruls Annette | CVP, EMEACLA | 4 | — | $238k (1) | 2026-08-28 |
| Stone Heisz Leslie | Director | 2 | — | $218k (1) | 2026-05-08 |
Shown here are the 8 who moved the most money, out of 17. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Dec 2025: 0 purchases and 9 sales, worth $5.2M. 2 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $205k |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 2 | $1.2M |
| Dec 2025 | 0 | $0 | 9 | $5.2M |
| Jan 2026 | 0 | $0 | 2 | $1.1M |
| Feb 2026 | 0 | $0 | 2 | $3.7M |
| Mar 2026 | 0 | $0 | 3 | $2.2M |
| Apr 2026 | 0 | $0 | 3 | $2.9M |
| May 2026 | 0 | $0 | 9 | $6.7M |
| Jun 2026 | 0 | $0 | 2 | $103k |
| Jul 2026 | 0 | $0 | 4 | $1.1M |
| Aug 2026 | 0 | $0 | 5 | $3.4M |
| Sep 2026 | 0 | $0 | 1 | $54k |
| Oct 2026 | 0 | $0 | 1 | $53k |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Edwards Lifesciences Corporation (EW) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
11 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Edwards Lifesciences has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 8, 2026, and a Form 4 arrives up to two business days after the trade.
16 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.